{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:48:27Z","timestamp":1790178507623,"version":"4.1.0"},"reference-count":84,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Obesity-related metabolic disorders, including diabetes, non-alcoholic fatty liver disease (NAFLD), and cardiovascular disease, increasingly threaten global health. Uncontrolled inflammation is a key pathophysiological factor in many of these conditions. In the human body, inflammatory responses generate specialized pro-resolving mediators (SPMs), which are crucial for resolving inflammation and restoring tissue balance. SPMs derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs) such as resolvins, protectins, and maresins hold promise in attenuating the chronic inflammatory diseases associated with lipid metabolism disorders. Recent research has highlighted the therapeutic potential of n-3 PUFA-derived metabolites in addressing these metabolic disorders. However, the understanding of the pharmacological aspects of SPMs, particularly in obesity-related metabolic disorders, remains limited. This review comprehensively summarizes recent advances in understanding the role of SPMs in resolving metabolic disorders, based on studies in animal models and humans. These studies indicate that SPMs have potential as therapeutic targets for combating obesity, as well as offering insights into their mechanisms of action.<\/jats:p>","DOI":"10.3390\/ijms25179598","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T08:46:22Z","timestamp":1725439582000},"page":"9598","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Deciphering the Potential Role of Specialized Pro-Resolving Mediators in Obesity-Associated Metabolic Disorders"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8109-7276","authenticated-orcid":false,"given":"Nahyun","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Biomedical Science and Engineering, Konkuk University, Seoul 05029, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8553-2107","authenticated-orcid":false,"given":"Ha Youn","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science and Engineering, Konkuk University, Seoul 05029, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2008.12.068","article-title":"Obesity and cardiovascular disease: Risk factor, paradox, and impact of weight loss","volume":"53","author":"Lavie","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11886-019-1107-y","article-title":"Epidemiology of Diabetes Mellitus and Cardiovascular Disease","volume":"21","author":"Glovaci","year":"2019","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1000367","article-title":"Body-mass index and mortality among 1.46 million white adults","volume":"363","author":"Hartge","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cmet.2013.10.006","article-title":"Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases","volume":"19","author":"Spite","year":"2014","journal-title":"Cell Metab."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.4062\/biomolther.2021.094","article-title":"Specialized Proresolving Mediators for Therapeutic Interventions Targeting Metabolic and Inflammatory Disorders","volume":"29","author":"Han","year":"2021","journal-title":"Biomol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.mam.2017.03.004","article-title":"Pro-resolving actions of SPM in adipose tissue biology","volume":"58","author":"Claria","year":"2017","journal-title":"Mol. Asp. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1172\/JCI97943","article-title":"Resolvins in inflammation: Emergence of the pro-resolving superfamily of mediators","volume":"128","author":"Serhan","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.bbalip.2010.08.002","article-title":"Specialized pro-resolving lipid mediators in the inflammatory response: An update","volume":"1801","author":"Bannenberg","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature13479","article-title":"Pro-resolving lipid mediators are leads for resolution physiology","volume":"510","author":"Serhan","year":"2014","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Pal, A., Gowdy, K.M., Oestreich, K.J., Beck, M., and Shaikh, S.R. (2020). Obesity-Driven Deficiencies of Specialized Pro-resolving Mediators May Drive Adverse Outcomes During SARS-CoV-2 Infection. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01997"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Al-Shaer, A.E., Pal, A., and Shaikh, S.R. (2021). Resolvin E1-ChemR23 Axis Regulates the Hepatic Metabolic and Inflammatory Transcriptional Landscape in Obesity at the Whole Genome and Exon Level. Front. Nutr., 8.","DOI":"10.3389\/fnut.2021.799492"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.2337\/db12-0828","article-title":"Impaired local production of proresolving lipid mediators in obesity and 17-HDHA as a potential treatment for obesity-associated inflammation","volume":"62","author":"Neuhofer","year":"2013","journal-title":"Diabetes"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.mce.2014.04.012","article-title":"Resolvin D1 reduces ER stress-induced apoptosis and triglyceride accumulation through JNK pathway in HepG2 cells","volume":"391","author":"Jung","year":"2014","journal-title":"Mol. Cell Endocrinol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1096\/fj.13-235614","article-title":"Resolvin D1 primes the resolution process initiated by calorie restriction in obesity-induced steatohepatitis","volume":"28","author":"Rius","year":"2014","journal-title":"FASEB J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.jacc.2011.06.063","article-title":"Omega-3 fatty acids and cardiovascular disease: Effects on risk factors, molecular pathways, and clinical events","volume":"58","author":"Mozaffarian","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.clnesp.2024.06.053","article-title":"Role of Omega-3 fatty acids eicosapentaenoic (EPA) and docosahexaenoic (DHA) as modulatory and anti-inflammatory agents in noncommunicable diet-related diseases\u2014Reports from the last 10 years","volume":"63","author":"Banaszak","year":"2024","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s12944-024-02207-9","article-title":"Role and mechanism of specialized pro-resolving mediators in obesity-associated insulin resistance","volume":"23","author":"Liu","year":"2024","journal-title":"Lipids Health Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1126\/science.1261375","article-title":"Expectations of brilliance underlie gender distributions across academic disciplines","volume":"347","author":"Leslie","year":"2015","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mam.2017.03.001","article-title":"Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology","volume":"58","author":"Serhan","year":"2017","journal-title":"Mol. Asp. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1084\/jem.192.8.1197","article-title":"Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing","volume":"192","author":"Serhan","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"101597","DOI":"10.1016\/j.smim.2022.101597","article-title":"E-series resolvin metabolome, biosynthesis and critical role of stereochemistry of specialized pro-resolving mediators (SPMs) in inflammation-resolution: Preparing SPMs for long COVID-19, human clinical trials, and targeted precision nutrition","volume":"59","author":"Serhan","year":"2022","journal-title":"Semin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1373\/clinchem.2012.190199","article-title":"Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation","volume":"58","author":"Mas","year":"2012","journal-title":"Clin. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"10525","DOI":"10.1074\/jbc.M112.340612","article-title":"Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid","volume":"287","author":"Isobe","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biochi.2013.11.006","article-title":"Confusion between protectin D1 (PD1) and its isomer protectin DX (PDX). An overview on the dihydroxy-docosatrienes described to date","volume":"99","author":"Balas","year":"2014","journal-title":"Biochimie"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.smim.2015.03.004","article-title":"The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution","volume":"27","author":"Serhan","year":"2015","journal-title":"Semin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.4049\/jimmunol.176.3.1848","article-title":"Anti-inflammatory actions of neuroprotectin D1\/protectin D1 and its natural stereoisomers: Assignments of dihydroxy-containing docosatrienes","volume":"176","author":"Serhan","year":"2006","journal-title":"J. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1084\/jem.20081880","article-title":"Maresins: Novel macrophage mediators with potent antiinflammatory and proresolving actions","volume":"206","author":"Serhan","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1096\/fj.11-201442","article-title":"Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain","volume":"26","author":"Serhan","year":"2012","journal-title":"FASEB J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1172\/JCI88884","article-title":"Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk","volume":"127","author":"Goldfine","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature05485","article-title":"Inflammation and metabolic disorders","volume":"444","author":"Hotamisligil","year":"2006","journal-title":"Nature"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1365-2796.2007.01852.x","article-title":"Obesity-induced inflammation: A metabolic dialogue in the language of inflammation","volume":"262","author":"Ferrante","year":"2007","journal-title":"J. Intern. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"7072","DOI":"10.1096\/fj.201802587R","article-title":"Leukocytes from obese individuals exhibit an impaired SPM signature","volume":"33","author":"Titos","year":"2019","journal-title":"FASEB J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.4049\/jimmunol.1201272","article-title":"Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat","volume":"189","author":"Claria","year":"2012","journal-title":"J. Immunol."},{"key":"ref_35","first-page":"e21592","article-title":"Changes in brown adipose tissue lipid mediator signatures with aging, obesity, and DHA supplementation in female mice","volume":"35","author":"Sainz","year":"2021","journal-title":"FASEB J."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Bashir, S., Sharma, Y., Jairajpuri, D., Rashid, F., Nematullah, M., and Khan, F. (2019). Alteration of adipose tissue immune cell milieu towards the suppression of inflammation in high fat diet fed mice by flaxseed oil supplementation. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0223070"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.4049\/jimmunol.1601031","article-title":"B Cell Activity Is Impaired in Human and Mouse Obesity and Is Responsive to an Essential Fatty Acid upon Murine Influenza Infection","volume":"198","author":"Kosaraju","year":"2017","journal-title":"J. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/JLB.3HI1017-405RR","article-title":"Frontline Science: A reduction in DHA-derived mediators in male obesity contributes toward defects in select B cell subsets and circulating antibody","volume":"106","author":"Crouch","year":"2019","journal-title":"J. Leukoc. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"618","DOI":"10.2337\/db12-0684","article-title":"Proresolution therapy for the treatment of delayed healing of diabetic wounds","volume":"62","author":"Tang","year":"2013","journal-title":"Diabetes"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12974-016-0777-2","article-title":"Resolvin RvD2 reduces hypothalamic inflammation and rescues mice from diet-induced obesity","volume":"14","author":"Pascoal","year":"2017","journal-title":"J. Neuroinflamm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.plefa.2019.07.001","article-title":"Effect of weight loss on neutrophil resolvins in the metabolic syndrome","volume":"148","author":"Barden","year":"2019","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"718","DOI":"10.4049\/jimmunol.1601543","article-title":"Neutrophil Resolvin E1 Receptor Expression and Function in Type 2 Diabetes","volume":"198","author":"Freire","year":"2017","journal-title":"J. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4539035","DOI":"10.1155\/2020\/4539035","article-title":"Decreased Plasma Maresin 1 Concentration Is Associated with Diabetic Foot Ulcer","volume":"2020","author":"Miao","year":"2020","journal-title":"Mediat. Inflamm."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12944-021-01518-5","article-title":"Low serum Maresin-1 levels are associated with non-alcoholic fatty liver disease: A cross-sectional study","volume":"20","author":"Fang","year":"2021","journal-title":"Lipids Health Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1096\/fj.10-178657","article-title":"Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice","volume":"25","author":"Hellmann","year":"2011","journal-title":"FASEB J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.4049\/jimmunol.1100225","article-title":"Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype","volume":"187","author":"Titos","year":"2011","journal-title":"J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.4049\/jimmunol.1502522","article-title":"Signaling and Immunoresolving Actions of Resolvin D1 in Inflamed Human Visceral Adipose Tissue","volume":"197","author":"Titos","year":"2016","journal-title":"J. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Entezari, M., Hashemi, D., Taheriazam, A., Zabolian, A., Mohammadi, S., Fakhri, F., Hashemi, M., Hushmandi, K., Ashrafizadeh, M., and Zarrabi, A. (2022). AMPK signaling in diabetes mellitus, insulin resistance and diabetic complications: A pre-clinical and clinical investigation. Biomed. Pharmacother., 146.","DOI":"10.1016\/j.biopha.2021.112563"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.cmet.2009.03.012","article-title":"AMPK: An emerging drug target for diabetes and the metabolic syndrome","volume":"9","author":"Zhang","year":"2009","journal-title":"Cell Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.arcmed.2020.05.002","article-title":"Resolvin D1 Ameliorates Nicotinamide-streptozotocin-induced Type 2 Diabetes Mellitus by its Anti-inflammatory Action and Modulating PI3K\/Akt\/mTOR Pathway in the Brain","volume":"51","author":"Bathina","year":"2020","journal-title":"Arch. Med. Res."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Bathina, S., and Das, U.N. (2021). Resolvin D1 Decreases Severity of Streptozotocin-Induced Type 1 Diabetes Mellitus by Enhancing BDNF Levels, Reducing Oxidative Stress, and Suppressing Inflammation. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041516"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1161\/CIRCRESAHA.116.309492","article-title":"Resolving Lipid Mediators Maresin 1 and Resolvin D2 Prevent Atheroprogression in Mice","volume":"119","author":"Viola","year":"2016","journal-title":"Circ. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.freeradbiomed.2022.06.231","article-title":"Resolution of inflammation is disturbed in acute ischemic stroke with diabetes mellitus and rescued by resolvin D2 treatment","volume":"188","author":"Tang","year":"2022","journal-title":"Free Radic. Biol. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1096\/fj.08-125674","article-title":"Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: A role for resolvins and protectins","volume":"23","author":"Horrillo","year":"2009","journal-title":"FASEB J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2016.05.001","article-title":"Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin","volume":"250","author":"Salic","year":"2016","journal-title":"Atherosclerosis"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1038\/sj.bjp.0707489","article-title":"Endogenous pro-resolving and anti-inflammatory lipid mediators: A new pharmacologic genus","volume":"153","author":"Serhan","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"E543","DOI":"10.1152\/ajpendo.00408.2017","article-title":"Protectin DX attenuates LPS-induced inflammation and insulin resistance in adipocytes via AMPK-mediated suppression of the NF-kappaB pathway","volume":"315","author":"Jung","year":"2018","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1124\/jpet.117.246686","article-title":"Protectin DX Ameliorates Hepatic Steatosis by Suppression of Endoplasmic Reticulum Stress via AMPK-Induced ORP150 Expression","volume":"365","author":"Jung","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/nm.3549","article-title":"Protectin DX alleviates insulin resistance by activating a myokine-liver glucoregulatory axis","volume":"20","author":"White","year":"2014","journal-title":"Nat. Med."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Jung, T.W., Kim, H.C., Abd El-Aty, A.M., and Jeong, J.H. (2017). Protectin DX ameliorates palmitate- or high-fat diet-induced insulin resistance and inflammation through an AMPK-PPARalpha-dependent pathway in mice. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-01603-9"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/1440-1681.13131","article-title":"Protectin DX ameliorates palmitate-induced hepatic insulin resistance through AMPK\/SIRT1-mediated modulation of fetuin-A and SeP expression","volume":"46","author":"Jung","year":"2019","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1096\/fj.201700394R","article-title":"The specialized proresolving lipid mediator maresin 1 protects hepatocytes from lipotoxic and hypoxia-induced endoplasmic reticulum stress","volume":"31","author":"Rius","year":"2017","journal-title":"FASEB J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/jcp.26096","article-title":"Maresin 1 inhibits TNF-alpha-induced lipolysis and autophagy in 3T3-L1 adipocytes","volume":"233","author":"Laiglesia","year":"2018","journal-title":"J. Cell Physiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1096\/fj.201600859R","article-title":"Maresin 1 improves insulin sensitivity and attenuates adipose tissue inflammation in ob\/ob and diet-induced obese mice","volume":"31","author":"Laiglesia","year":"2017","journal-title":"FASEB J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s13105-020-00775-9","article-title":"Maresin 1 regulates insulin signaling in human adipocytes as well as in adipose tissue and muscle of lean and obese mice","volume":"77","author":"Sainz","year":"2021","journal-title":"J. Physiol. Biochem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2337\/db06-0911","article-title":"Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation","volume":"56","author":"Hosogai","year":"2007","journal-title":"Diabetes"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.surg.2008.08.038","article-title":"Inflammation in obesity-related diseases","volume":"145","year":"2009","journal-title":"Surgery"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1074\/jbc.M109498200","article-title":"Mapping of early signaling events in tumor necrosis factor-alpha -mediated lipolysis in human fat cells","volume":"277","author":"Ryden","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/jcb.10565","article-title":"TNF-alpha induction of lipolysis is mediated through activation of the extracellular signal related kinase pathway in 3T3-L1 adipocytes","volume":"89","author":"Souza","year":"2003","journal-title":"J. Cell Biochem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1007\/s00125-012-2671-5","article-title":"The ghrelin O-acyltransferase-ghrelin system reduces TNF-alpha-induced apoptosis and autophagy in human visceral adipocytes","volume":"55","author":"Rodriguez","year":"2012","journal-title":"Diabetologia"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Martinez-Fernandez, L., Burgos, M., Sainz, N., Laiglesia, L.M., Arbones-Mainar, J.M., Gonzalez-Muniesa, P., and Moreno-Aliaga, M.J. (2023). Maresin 1 Exerts a Tissue-Specific Regulation of Adipo-Hepato-Myokines in Diet-Induced Obese Mice and Modulates Adipokine Expression in Cultured Human Adipocytes in Basal and Inflammatory Conditions. Biomolecules, 13.","DOI":"10.3390\/biom13060919"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ijo.2017.226","article-title":"Maresin 1 mitigates liver steatosis in ob\/ob and diet-induced obese mice","volume":"42","author":"Laiglesia","year":"2018","journal-title":"Int. J. Obes."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1074\/jbc.RA117.000885","article-title":"Maresin 1 attenuates NAFLD by suppression of endoplasmic reticulum stress via AMPK-SERCA2b pathway","volume":"293","author":"Jung","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-physiol-021115-105339","article-title":"Understanding the Physiology of FGF21","volume":"78","author":"Fisher","year":"2016","journal-title":"Annu. Rev. Physiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.celrep.2017.06.017","article-title":"RORalpha Induces KLF4-Mediated M2 Polarization in the Liver Macrophages that Protect against Nonalcoholic Steatohepatitis","volume":"20","author":"Han","year":"2017","journal-title":"Cell Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1172\/JCI124219","article-title":"A maresin 1\/RORalpha\/12-lipoxygenase autoregulatory circuit prevents inflammation and progression of nonalcoholic steatohepatitis","volume":"129","author":"Han","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/jn\/nxac075","article-title":"Enriched Marine Oil Supplement Increases Specific Plasma Specialized Pro-Resolving Mediators in Adults with Obesity","volume":"152","author":"Regan","year":"2022","journal-title":"J. Nutr."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.jacl.2016.02.013","article-title":"Effects of DHA-enriched fish oil on monocyte\/macrophage activation marker sCD163, asymmetric dimethyl arginine, and insulin resistance in type 2 diabetic patients","volume":"10","author":"Toupchian","year":"2016","journal-title":"J. Clin. Lipidol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Jacobo-Cejudo, M.G., Valdes-Ramos, R., Guadarrama-Lopez, A.L., Pardo-Morales, R.V., Martinez-Carrillo, B.E., and Harbige, L.S. (2017). Effect of n-3 Polyunsaturated Fatty Acid Supplementation on Metabolic and Inflammatory Biomarkers in Type 2 Diabetes Mellitus Patients. Nutrients, 9.","DOI":"10.3390\/nu9060573"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"102154","DOI":"10.1016\/j.plefa.2020.102154","article-title":"DHA-enriched fish oil reduces insulin resistance in overweight and obese adults","volume":"159","author":"Abbott","year":"2020","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1017\/S0007114520000495","article-title":"Combined effect of n-3 fatty acids and phytosterol esters on alleviating hepatic steatosis in non-alcoholic fatty liver disease subjects: A double-blind placebo-controlled clinical trial","volume":"123","author":"Song","year":"2020","journal-title":"Br. J. Nutr."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Fisk, H.L., Childs, C.E., Miles, E.A., Ayres, R., Noakes, P.S., Paras-Chavez, C., Antoun, E., Lillycrop, K.A., and Calder, P.C. (2022). Dysregulation of Subcutaneous White Adipose Tissue Inflammatory Environment Modelling in Non-Insulin Resistant Obesity and Responses to Omega-3 Fatty Acids\u2014A Double Blind, Randomised Clinical Trial. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.922654"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1464-5491.2009.02869.x","article-title":"Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus","volume":"27","author":"Wong","year":"2010","journal-title":"Diabet. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12933-017-0523-9","article-title":"Treatment with high-dose n-3 PUFAs has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes","volume":"16","author":"Poreba","year":"2017","journal-title":"Cardiovasc. Diabetol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/17\/9598\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:48:38Z","timestamp":1760111318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/17\/9598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":84,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["ijms25179598"],"URL":"https:\/\/doi.org\/10.3390\/ijms25179598","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,4]]}}}